Tags

Type your tag names separated by a space and hit enter

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
J Am Coll Cardiol. 2006 May 16; 47(10):1919-26.JACC

Abstract

Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for the treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking. In four large trials, after one year of treatment, rimonabant 20 mg led to greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is also associated with favorable changes in serum lipid levels and an improvement in glycemic control in prediabetes patients and in type 2 diabetic patients. At the same dose, rimonabant significantly increased cigarette smoking quit rates as compared with placebo. Rimonabant seems to be well tolerated, with a primary side effect of mild nausea. As an agent with a novel mechanism of action, rimonabant has a potential to be a useful adjunct to lifestyle and behavior modification in treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking.

Authors+Show Affiliations

Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16697306

Citation

Gelfand, Eli V., and Christopher P. Cannon. "Rimonabant: a Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk Factors." Journal of the American College of Cardiology, vol. 47, no. 10, 2006, pp. 1919-26.
Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006;47(10):1919-26.
Gelfand, E. V., & Cannon, C. P. (2006). Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. Journal of the American College of Cardiology, 47(10), 1919-26.
Gelfand EV, Cannon CP. Rimonabant: a Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk Factors. J Am Coll Cardiol. 2006 May 16;47(10):1919-26. PubMed PMID: 16697306.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. AU - Gelfand,Eli V, AU - Cannon,Christopher P, Y1 - 2006/04/24/ PY - 2005/11/29/received PY - 2005/12/14/accepted PY - 2006/5/16/pubmed PY - 2006/5/26/medline PY - 2006/5/16/entrez SP - 1919 EP - 26 JF - Journal of the American College of Cardiology JO - J Am Coll Cardiol VL - 47 IS - 10 N2 - Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for the treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking. In four large trials, after one year of treatment, rimonabant 20 mg led to greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is also associated with favorable changes in serum lipid levels and an improvement in glycemic control in prediabetes patients and in type 2 diabetic patients. At the same dose, rimonabant significantly increased cigarette smoking quit rates as compared with placebo. Rimonabant seems to be well tolerated, with a primary side effect of mild nausea. As an agent with a novel mechanism of action, rimonabant has a potential to be a useful adjunct to lifestyle and behavior modification in treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking. SN - 1558-3597 UR - https://www.unboundmedicine.com/medline/citation/16697306/Rimonabant:_a_cannabinoid_receptor_type_1_blocker_for_management_of_multiple_cardiometabolic_risk_factors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)00554-7 DB - PRIME DP - Unbound Medicine ER -